DK0668763T3 - Anvendelse af phenserin til fremstillingen af lægemidler til behandlingen af kognitive sygdomme - Google Patents

Anvendelse af phenserin til fremstillingen af lægemidler til behandlingen af kognitive sygdomme

Info

Publication number
DK0668763T3
DK0668763T3 DK94903295T DK94903295T DK0668763T3 DK 0668763 T3 DK0668763 T3 DK 0668763T3 DK 94903295 T DK94903295 T DK 94903295T DK 94903295 T DK94903295 T DK 94903295T DK 0668763 T3 DK0668763 T3 DK 0668763T3
Authority
DK
Denmark
Prior art keywords
phenserin
drugs
manufacture
treatment
cognitive disorders
Prior art date
Application number
DK94903295T
Other languages
English (en)
Inventor
Harold W Holloway
Setsu Iijima
Arnold Brossi
Nigel H Greig
Timothy T Soncraint
Stanley I Rapoport
Edward L Spangler
Donald K Ingram
Xue Feng Pei
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Application granted granted Critical
Publication of DK0668763T3 publication Critical patent/DK0668763T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK94903295T 1992-11-23 1993-11-23 Anvendelse af phenserin til fremstillingen af lægemidler til behandlingen af kognitive sygdomme DK0668763T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/980,399 US5409948A (en) 1992-11-23 1992-11-23 Method for treating cognitive disorders with phenserine
PCT/US1993/011423 WO1994012176A1 (en) 1992-11-23 1993-11-23 Use of phenserine to treat cognitive disorders

Publications (1)

Publication Number Publication Date
DK0668763T3 true DK0668763T3 (da) 2002-06-03

Family

ID=25527533

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94903295T DK0668763T3 (da) 1992-11-23 1993-11-23 Anvendelse af phenserin til fremstillingen af lægemidler til behandlingen af kognitive sygdomme

Country Status (11)

Country Link
US (1) US5409948A (da)
EP (1) EP0668763B1 (da)
JP (1) JP3778363B2 (da)
AT (1) ATE213411T1 (da)
AU (1) AU693428B2 (da)
CA (1) CA2149924C (da)
DE (1) DE69331605T2 (da)
DK (1) DK0668763T3 (da)
ES (1) ES2173111T3 (da)
PT (1) PT668763E (da)
WO (1) WO1994012176A1 (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2255170T3 (es) * 1997-07-09 2006-06-16 Axonyx Inhibidores de butirilcolinesterasa altamente selectivos para el tratamiento y diagnostico de demencias y de la enfermedad de alzheimer.
WO2003032827A1 (en) * 2001-08-03 2003-04-24 Robert Becker Method for reliable measurement in medical care and patient self monitoring
US6495700B1 (en) 2002-01-09 2002-12-17 Axonyx, Inc. Process for producing phenserine and its analog
US20040024043A1 (en) * 2002-03-22 2004-02-05 Nigel Greig Method for treating cognitive disorders
US7612078B2 (en) 2003-03-31 2009-11-03 Epix Delaware, Inc. Piperidinylamino-thieno[2,3-D] pyrimidine compounds
JP4676961B2 (ja) * 2003-10-21 2011-04-27 コルシド・ファーマシューティカルズ・インコーポレイテッド コリンエステラーゼを阻害し、薬理活性物質を放出するカルバモイルエステル類
US20050182044A1 (en) * 2004-02-17 2005-08-18 Bruinsma Gosse B. Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate
WO2005089746A1 (en) * 2004-03-19 2005-09-29 Axonyx, Inc. Dosage titration for treatment of cognitive disorders
US20070213388A1 (en) * 2004-03-19 2007-09-13 Bruinsma Gosse B Acetylcholinesterase Inhibitors and N-Methyl-D-Aspartate Antagonists Useful in the Treatment of of Cognitive Disorders
US7488736B2 (en) 2004-05-17 2009-02-10 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
CA2508585A1 (en) * 2004-06-01 2005-12-01 Axonyx, Inc. Transdermal delivery system for treatment of cognitive disorders
EP1604686A1 (en) * 2004-06-08 2005-12-14 Axonyx, Inc. Use of phenserine and a HMG CoA reductase inhibitor for delaying Alzheimer's disease progression
US7598265B2 (en) 2004-09-30 2009-10-06 Epix Delaware, Inc. Compositions and methods for treating CNS disorders
US7407966B2 (en) 2004-10-07 2008-08-05 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
US7576211B2 (en) 2004-09-30 2009-08-18 Epix Delaware, Inc. Synthesis of thienopyridinone compounds and related intermediates
US20060194723A1 (en) * 2005-02-28 2006-08-31 Rabinoff Michael D Novel medication treatment and delivery strategies for Alzheimer's Disease, other disorders with memory impairment, and possible treatment strategies for memory improvement
WO2006138385A2 (en) * 2005-06-14 2006-12-28 Cancog Technologies Inc.24 Use of phenserine and analogs to treat behavioral problems and improve trainability
MX2009008288A (es) * 2007-02-02 2009-12-01 Colucid Pharmaceuticals Inc Compuestos que inhiben la colinesterasa.
RU2327480C1 (ru) 2007-05-23 2008-06-27 Виктор Иванович Рощин Активный ингредиент лекарственного средства, лекарственное средство, фармацевтическая композиция и способ лечения больных с дементным синдромом
JP2010533717A (ja) * 2007-07-18 2010-10-28 コルシド・ファーマシューティカルズ・インコーポレイテッド 覚醒を促進する方法
US8593728B2 (en) * 2009-02-19 2013-11-26 Toyota Motor Engineering & Manufacturing North America, Inc. Multilayer photonic structures
EP2445877B1 (en) 2008-12-03 2014-07-23 Nanotherapeutics, Inc. Bicyclic compounds and methods of making and using same
AU2010273977A1 (en) * 2009-07-17 2012-02-02 Allergan, Inc. Compositions comprising a cholinesterase inhibitor for treating cognitive disorders
US20120225922A1 (en) 2011-03-04 2012-09-06 Qr Pharma Effective Amounts of (3aR)-1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo [2,3-b]indol-5-yl Phenylcarbamate and Methods of Treating or Preventing Neurodegeneration
CA2994974C (en) 2015-08-14 2024-04-09 Qr Pharma Methods of treatment or prevention of acute brain or nerve injuries
US10111860B1 (en) 2016-01-15 2018-10-30 Aristea Translational Medicine Corporation Compositions and methods for treating concussion
US10864192B2 (en) 2016-01-15 2020-12-15 Aristea Translational Medicine Corporation Compositions and methods for inhibiting brain trauma-induced neurodegeneration and related conditions
US20180338950A1 (en) 2017-05-24 2018-11-29 Qr Pharma, Inc. Prevention or Treatment of Disease States Due to Metal Dis-Homeostasis Via Administration of Posiphen to Healthy or Sick Humans
US12582632B2 (en) 2021-05-18 2026-03-24 Annovis Bio, Inc. Inhibition of neurological injuries due to infections via administration of Butanetap and analogs thereof
WO2025017530A1 (en) 2023-07-19 2025-01-23 Assia Chemical Industries Ltd. Solid state forms of buntanetap and process for preparation thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US479107A (en) * 1892-07-19 oesterreich
US4791107A (en) * 1986-07-16 1988-12-13 Hoechst-Roussel Pharmaceuticals, Inc. Memory enhancing and analgesic 1,2,3,3A,8,8A-hexahydro-3A,8 (and) 1,3A,8)-di(and tri)methylpyrrolo(2,3-B)indoles, compositions and use
DE3843239C1 (da) * 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
US4971992A (en) * 1989-03-27 1990-11-20 Hoechst-Roussel Pharmaceuticals Inc. Carbonate derivatives of eseroline
US4996201A (en) * 1989-08-02 1991-02-26 Warner-Lambert Co. 4-(N-substituted amino)-2-butynyl-1-carbamates and thiocarbamates and derivatives thereof as centrally acting muscarinic agents
US4914102A (en) * 1989-09-28 1990-04-03 Hoechst Roussel Pharmaceuticals, Inc. N-aminocarbamates related to physostigmine, pharmacentical compositions and use
US5077289A (en) * 1989-11-30 1991-12-31 Hoechst Roussel Pharmaceuticals Inc. Memory enhancing and analgesic aminocarbonylcarbamates related to physostigmine
US5171750A (en) * 1991-09-26 1992-12-15 The United States Of America As Represented By The Department Of Health And Human Services Substituted phenserines as specific inhibitors of acetylcholinesterase

Also Published As

Publication number Publication date
AU5729094A (en) 1994-06-22
CA2149924C (en) 2006-01-31
JP3778363B2 (ja) 2006-05-24
PT668763E (pt) 2002-08-30
CA2149924A1 (en) 1994-06-09
US5409948A (en) 1995-04-25
AU693428B2 (en) 1998-07-02
DE69331605D1 (de) 2002-03-28
ATE213411T1 (de) 2002-03-15
WO1994012176A1 (en) 1994-06-09
EP0668763B1 (en) 2002-02-20
EP0668763A1 (en) 1995-08-30
JPH08505130A (ja) 1996-06-04
DE69331605T2 (de) 2002-10-31
ES2173111T3 (es) 2002-10-16

Similar Documents

Publication Publication Date Title
ES2173111T3 (es) Uso de fenserina para la preparacion de medicamentos para el tratamiento de desordenes cognoscitivos.
DK1574209T3 (da) Fremgangsmåde til behandling af ophthalmiske sygdomme
FI971116L (fi) Fotodynaaminen terapia selektiivisessä solujen inaktivoinnissa veressä sekä immuunijärjestelmän häiriötautien hoito
DE69825292D1 (de) Verwendung von inosine zur herstellung eines medikamentes zur stimulierung des axonwachstums von zns-neuronen
DE69213814D1 (de) Melatoninderivate zur Behandlung von Schlafstörungen und zur Pre-Anästhesie
EP0348353A3 (en) The use of physiologically active substances for the manufacture of drugs for cerebral and neuronal diseases
DK0501705T3 (da) Anvendelse af tomoxetin til behandling af sygdomme i de nedre urinveje
DE69424777D1 (de) 3,4-diarylchromane zur behandlung von dermatitis
RU94002133A (ru) 6-хлор-5-фтор-3-(2-теноил)-2-оксиндол-1-карбоксамид как аналгезирующее и противовоспалительное средство
LT97135A (en) Use of melatonin in the manufacture of a medicament for treating patients suffering from drug addiction
DE59605959D1 (de) Verwendung von Immunglobulin-Präparationen zur Herstellung eines Medikaments zur oralen Verabreichung zur Behandlung und Prophylaxe chronischer Schmerzzustände
PL338673A1 (en) Application of fanquinone in treating alzheimer disease
FI973185A0 (fi) Melatoniinin käyttö lääkeriippuvuudesta kärsivien potilaiden hoitoon
DE69100171D1 (de) Synergistische kombination zur ophthalmischen verwendung.
RU93050675A (ru) Способ коррекции психофизиологического состояния человека
NO984196L (no) FremgangsmÕte for behandling av stoffmisbruk
DE68909750D1 (de) Vorrichtung zur therapeutischen behandlung von lumbago sowie lumbago/ischias.
NO960347D0 (no) Anvendelse av benzydamid ved behandling av patologiske tilstander forårsaket av TNF
DE69800906D1 (de) Verwendung von Olanzapine zur Herstellung eines Arzneimittels zur Behandlung der zerebralen fokalen Ischämie
ITMI941939A0 (it) Derivati purinici ed 8-azapurinici atti al trattamento terapeutico dell'aids
KR920009403A (ko) 수면장해 치료용 이미다조벤조디아제핀
EA200200559A1 (ru) Способ лечения и профилактики нейродегенеративных состояний
EE04951B1 (et) R-(+)-alfa-(2,3-dimetoksfenl)-1-[2-(4-fluorofenl)etl]-4-piperidiinmetanooli kasutamine uneh„irete raviks
RU95111888A (ru) Способ лечения периферических поражений лицевого нерва
UA22007A (uk) Спосіб лікуваhhя хроhічhого hеспецифічhого простатиту